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Purpose:  The  aim  of this  prospective  study  was  to examine  the  diagnostic  value  of dual-energy  CT  (DECT)
in the assessment  of  response  of HCC  after radioembolisation  (RE).
Material  and  methods:  40 HCC  patients  with  82 measurable  target  lesions  were  included  in  this  study.  At
baseline  and  follow-up  examination  target  lesions  were  evaluated  with  (IU),  AASLD  and  Choi  measure-
ment  criteria.  Disease  control  was  deﬁned  as  the  sum  of  complete  response  (CR),  partial  response  (PR),
progression  disease  (PD)  and stable  disease  (SD).
Results: With  Choi  and  IU more  patients  were  considered  than  PR  and  less  than  PD  and  SD.  According  to
AASLD  more  patients  were  measured  as SD  and  PD than  PR.  26/40  patients  were  classiﬁed  as PR  with  IU.
In  contrast  measurements  with  AASLD  in  only  8/26  patients  were  also  classiﬁed  as  PR.  6/12  SD  patients
measured  with  IU were  measured  as PD  with  AASLD.  4/26  patients  classiﬁed  with  IU  as  PR were described
as SD  with  CHOI,  10/14  SD  patients  measured  with  CHOI  were  SD  according  to  IU,  the  other  4  patients
were  PR  with  IU.  2/4 PD  patients  according  to CHOI  were SD  with  IU.
Conclusion:  More  patients  by  IU  were  classiﬁed  as  SD  versus PD  and  PR  versus  SD.  We  attribute  this  to
the  more  detailed  consideration  of  the  HU  differences  between  the  virtual  native  and  contrast-enhanced
series  generated  by  DECT.  Iodine  uptake  (IU)  in  HCC  measured  and  visualized  with  DECT  is a promising
imaging  method  for  the  assessment  of  treatment  response  after radioembolisations.
Key  points:  —dual  energy  CT of  hypervascular  tumors  such  as  HCC  allows  to  quantify  contrast  enhance-
ment  without  native  imaging.
—this can  be used  to evaluate  the  therapy  response  after  Radioembolization.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd. This  is an open  access  article  under  the  CC  BY-NC-ND. Introduction
Selective internal radiation therapy (SIRT) with 90yttrium
icrospheres − also known as radioembolisation (RE)- is a rapidly
volving therapy option for inoperable HCC [1–6].
The response to treatment is assessed by critical clinical and
aboratory parameters as well as by post- interventional cross-
ectional imaging including CT or MRI. In addition to the changes
n tumor size vascularization is an important marker for therapy
onitoring [7–15].
In responders HCC lesions ideally show a reduction in size and
ecreased hyper-vascularity after RE. In some cases, a stable or
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352-0477/© 2016 The Author(s). Published by Elsevier Ltd. This is an open access articl
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even increased tumor size (so-called pseudo-progression) with
reduced blood ﬂow to the tumor mass is reported [16]. This may
be attributed to tumor necrosis, hemorrhage and edema leading to
increased tumor size.
Assessment of tumor response should incorporate the reduction
in viable tumor burden, deﬁned by the area (EASL) [17] or diameter
(AASLD) [18] measurement of contrast enhancing tumor on arte-
rial phase imaging to assess the tumor response. AASLD diameter
measurement of viable tumor is used in clinic and considered as the
standard assessment of treatment efﬁciency in patients receiving
antiangiogenic therapy [19].
Choi et al. have proposed the measurement of CT density
as a potential indicator of gastrointestinal stromal tumor (GIST)
response in patients undergoing targeted therapy [20].In rare cases, however, HCC response may  result in increased
density because of the intratumoral hemorrhage, which is a rare
effect observed during sorafenib therapy [15], thus result mislead
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Table 1
Patient demographics.
Variable Value
Age(Years)
mean 66.2 + - 8.3
range 52–77
Gender
Males 24
Females 16
Etiology of liver cirrhosis
Ethanol abuse 16
HBV 12
HCV 10
NASH 2
Child-Pugh class
A 16
B 24
Baseline AFP
Mean (ng/ml) 438
Range 92–4583J. Altenbernd et al. / European Jour
umor density measurements and failed Choi response assesse-
ent. Therefore, ideally, new parameter directly related with
eovascularisation should be acquired to assess the density differ-
nces related to contrast medium accumulation, or, those related
o vital and vascularized tumor tissue [7].
Dynamic contrast-enhanced CT perfusion has been explored as
otential new method for assessing response of tumor vasculariza-
ion to antiangiogenic therapy but in clinic practice it is prohibited
egarding the limitations (e.g. limited coverage of all tumor sites,
nstandardized postprocessing, radiation dose) [21].
A recent development in CT has been the introduction of dual
nergy technology [22]. On such CT systems, two  X-ray tubes can
e operated at different tube currents, making dual energy scan-
ing feasible. Dual energy CT implies simultaneous acquisition of
ata sets at two different photon spectra in a single CT examina-
ion [23] resulting in the ability to reconstruct the data at 80-kVp,
40-kVp, and weighted-average. The weighted-average data set is
 combination of image data from the 80- and 140-kVp data sets
nd can be used to generate a virtual 120-kVp data set. In addi-
ion, virtual non-enhanced data sets can be reconstructed by using
ost-processing algorithms [24,25].
One important advantage of dual energy CT (DECT) when com-
ared with a single-source system is the option to use the two
ubes at different tube currents offering differentiation of materi-
ls of non-equal density. The higher the difference in the two  tube
urrents (e.g. 80 kVp and 140 kVp) used for imaging the better is
he differentiation between two materials of different density [23].
ased on these advantages potential applications of dual energy
T when evaluating the abdomen are for example [26]: Quantiﬁ-
ation and visualization of contrast enhancement, reconstruction
f virtual non-enhanced images from the existing data sets obvi-
ting the need for additional non-enhanced scans. Consequently,
adiation exposure for the patient may  be reduced. Furthermore,
alciﬁcations may  be quantiﬁed and anatomical structures of high
ttenuation (such as the bone) can be removed semiautomatically.
DECT) allows selective quantiﬁcation and visualization of
odine-related density differences and improves the ability to
etect contrast agent and to distinguish high-density substances
reated by iodine from those created by hemorrhage [7,21].
The aim of this prospective study was to examine the diagnostic
alue of iodine uptake (IU) measured with dual-energy CT (DECT)
or the assessment of therapy response after RE in patients with
CC compared to measurements based on AASLD and Choi. We
ypothesize that DECT may  help to determine the exact contrast
ptake in tumors, which could represent an important response
arker in addition to changes in size.
. Material and methods
.1. Patient population
We  prospectively analyzed data of all HCC patients who received
adioembolisation and monitoring by DECT in our institution
etween May  2009 and January 2010. Baseline contrast enhanced
ECT scan was obtained three weeks before treatment and at least
ne follow-up scan was obtained 12 weeks after radioembolisa-
ion. If bilobar disease was present radioembolisation treatment
as staged and follow-up scan was performed 12 weeks after the
ast treatment.
The inclusion criteria were:inoperable (due to size, localization) HCC; hepatic function
Child–Pugh Class A or B; presence of a measurable target
lesion showing intratumoral arterial enhancement in contrastAFP, -fetoprotein; HBV, hepatits B virus; HCV, hepatitis C virus; NASH, nonalcoholis
steatohepatitis.
enhanced DECT [27]. The measurable diameter was at least 1 cm
and the lesion was  suitable for repeated measurements;
• the exclusion criteria were: prior systemic treatment; contrast
allergy; renal dysfunction; hypoenhancing tumor without wash
out; prior transarterial chemoembolization (TACE), or radiofre-
quence ablation (RFA).
85 HCC patients were examined in our institution with DECT in
this period, including 60 patients treated with radioembolisation.
Finally, 40 out of 60 patients (34 men  and 26 women) with 82 mea-
surable target lesions (median 2 lesions/patient, range 1–4) were
analyzed.
20 out of 60 patients were excluded from analysis 4
patients with no measurable target lesion, 16 patients with
prior systemic treatment/transarterial chemoembolisation
(TACE)/radiofrequence ablation (RFA).
This study was approved by our institutional review board and
all patients provided written informed consent prior to their par-
ticipation. Patientsı´ characteristics are displayed in Table 1.
2.2. DECT protocol
All CT scans were performed on a dual-source multi– detec-
tor scanner (Somatom DeﬁnitionTM Dual Source; Siemens Medical
Solutions, Forchheim, Germany).
Patients were positioned slightly off center to the left to ensure
complete coverage of the liver by the smaller ﬁeld of view of detec-
tor B.
After intravenous injection of a non-ionic contrast agent (1,5 ml
per kilogram of body weight, Xenetix 300TM, Guerbet, Sulzbach,
Germany, mean body weight 73 + - 17 kg, mean contrats amount
103 + - 10 ml,  ﬂow rate 4 ml/s) via an automated dual-syringe power
injector (Accutron CT-D, Medtron, Saarbrücken, Germany) scan-
ning of the arterial phase (AP) during inspiratory breath-hold was
started. All patients were scanned in cranio-caudal direction from
the dome of the liver to the iliac crest.
The timing for the AP scan was  determined using the care bolus
technique (Siemens Healthcare, Forchheim, Germany), AP scanning
was automatically started 7 s after the attenuation coefﬁcient of
abdominal aortic blood reached 120 HU. The portal venous phase
(PVP) images were acquired 30 s after AP.
All AP and PVP images were obtained in the dual energy (DE)
mode. The DE scan was acquired with a detector collimation of
232 J. Altenbernd et al. / European Journal of Radiology Open 3 (2016) 230–235
Table 2
Evaluation criteria used in the assessment of target lesion response.
AASLD CHOI IU
CR No viable lesion No viable lesions No viable lesions
PR  ≥30% decrease of diameter ≥10% decrease of diameter or ≥15% decrease
in tumor density (HU)
≥10% decrease of diameter or ≥15% decrease
in tumor iodine uptake (HU)
PD  ≥20% increase of diameter ≥10% increase of diameter and no PR by tumor
density (HU)
≥10% increase of diameter and no PR by tumor
iodine uptake (HU)
SD  Neither sufﬁcient decrease for PR nor PD Neither sufﬁcient decrease for PR nor PD Neither sufﬁcient decrease for PR nor PD
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CFig. 1. The dual energy scanner generates three different series of image
4 × 1.2 mm on both detectors; slice thickness 3.0; rotation time,
.5 s; pitch, 0.6; voltage tube A at 140 kVp and a reference value of
6 mAs  and tube B at 80 kVp and a reference value of 404 mAs. For
oth tubes, an online dose modulation (Care DOSE 4DTM, Siemens
edical Solutions) was used. For all scans, the gantry rotation speed
as 0.5 s.
To calculate the mean iodine-uptake (IU) and density measure-
ents of the tumor in the arterial contrast phase the dual energy
oftware (Dual EnergyTM, Siemens Medical Solutions) was used.
he contrast medium enhancement was quantiﬁed based on a
hree material decomposition assuming the main components fat,
oft tissue and iodine. On the basis of calibration measurements
erformed by the manufacturer, the algorithm is able to trans-
orm spectral information of dual energy data into absolute values
f iodine content. Additionally, the maximum transversal viable
umor diameter (according to AASLD criteria [18]) of each target
esion was measured properly in arterial phase CT images. Viable
umor was deﬁned astumor tissue enhancing in arterial phase CE-
ECT examinations after contrast medium injection [9,10].
DECT studies were evaluated retrospectively by two  radiologists
ith more than 10 years of diagnostic experiences in a consensus
ode. At baseline and follow-up examination target lesions were
valuated with AASLD and Choi measurement criteria (Table 2). AFP
-fetoprotein) was measured before and 12 weeks after RE.
The response evaluation was performed on a per lesion basis;
e did not take into consideration changes in non-target lesions,
he appearance of new lesions nor change in extrahepatic tumor
oad.
Disease control was deﬁned as the sum of complete response
CR), partial response (PR) and stable disease (SD). However, the
bjective response (OR) was deﬁned as the sum of CR and PR, similar
o other studies [14]. Unidimensional maximum transversal diam-
ter of viable tumor was measured manually according to AASLD
riteria [9,10]. Progressive disease (PD) refered to 20% increase, par-
ial response (PR) to 30% decrease in diameter, complete response
CR) refered to complete disappearance of measurable lesions and
table disease (SD) is deﬁned as a status between PD and PR.
umor CT density was assessed using CT attenuation coefﬁcients
s described by Choi and colleagues in GIST [13]. PR according to
hoi criteria was  deﬁned as a decrease in tumor density (measuredkVp images (a.), 140-kVp images (b.), and weighted-average images (c.).
in Hounsﬁeld units, HU) of 15% or more on CT or a decrease in target
size (largest diameter of target lesion, mm)  of 10% or more.
2.3. Postprocessing and image reconstruction
Axial post-contrast images were reconstructed using a section
thickness and an increment of 3 mm.  The dual energy scanner
generates three different series of images: 80-kV images, 140-kV
images, and weighted-average images, which are based on atten-
uation information on scans obtained from both detectors, using
70% information from the high-kVp and 30% from the low-kVp
scan (Fig. 1). Weighted-average images are similar to a 120-kVp
scan of the abdomen and were used for measurements of contrast
material uptake. Images were loaded onto a dedicated dual energy
postprocessing workstation (syngo MMWP;  Siemens Medical Solu-
tions, Forchheim, Germany). Overlay images were reconstructed
from the original data set by visualization of iodine. This calculation
was based on a so-called three-material decomposition: Assuming
that every voxel in the abdomen is composed of fat, soft tissue, and
iodine, the algorithm generated a map  that encodes the iodine dis-
tribution in each individual CT voxel. This map  can subsequently be
used to identify iodine in the image, resulting in an overlay image.
2.4. Qualitative analysis
Readers were asked to scroll through the sets of images on a
dedicatd workstation (syngo MMWP,  Siemens Medical Solutions)
and to change window and/or level settings according to their
personal preference. The greatest diameter and CT-attenuation
of hypervascularized liver lesions in arterial phase in pre- and
posttherpeutic DECT was  measured. CT attenuation measurements
were performed on axial images and adjusted manually.
2.5. Statistical analysis
Variables were expressed as mean ± standard deviation. Com-
parisons between groups were done with the 2 test, the
consistency evaluation with kappa statistical analysis an compar-
isons in groups were done using the one sample t-test and the
correlations between different groups using Spearman correlation
J. Altenbernd et al. / European Journal of Radiology Open 3 (2016) 230–235 233
Table  3
Response evaluation: comparison of evaluation criteria.
CR PR PD SD
AASLD 0 8/40 14/40 18/40
CHOI 0 22/40 4/40 14/40
IU  0 26/40 2/40 12/40
Table 4
Comparison of response evaluation results: AASLD vs. IU.
IU
AASLD CR PR PD SD
∑
CR 0 0 0 0 0
PR 0 8 0 0 8
PD 0 6 2 6 14
SD 0 12 0 6 18∑
0 26 2 12
Table 5
Comparison of response evaluation results: CHOI vs. IU.
IU
CHOI CR PR PD SD
∑
CR 0 0 0 0 0
PR  0 22 0 0 22
PD  0 0 2 2 4
SD  0 4 0 10 14∑
0 26 2 12
Table 6
Comparison of response evaluation results: AASLD vs. CHOI.
CHOI
AASLD CR PR PD SD
∑
CR 0 0 0 0 0
PR 0 8 0 0 8
PD 0 4 4 6 14
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Table 7
Response parameters at baseline and follow-up.
Baseline Follow-up P value
AASLD (mm)  53.3 ± 23.4 50.2 ± 31.3 0.26
CHOI (HU) 56.6 ± 32.7 32.3 ± 21.8 <0.005SD 0 10 0 8 18∑
0 22 4 14
nalysis. Signiﬁcance was deﬁned by P < 0.05. All statistical analy-
es were performed with the SPSS software package (version 21.0;
PSS, Inc., Chicago, Ill).
. Results
The treatment response evaluated according to AASLD, Choi and
U is listed in Table 3. With Choi and IU more patients were consid-
red as PR than as PD and SD. According to AASLD more patients
ere measured as SD and PD than as PR.
26/40 patients were classiﬁed as PR with IU. In contrast mea-
urements with AASLD in only 8 of these 26 patients were also
lassiﬁed as PR, in 6/26 patients as PD and in 12/26 patients as
D. 6/12 SD patients measured with IU were measured as PD with
ASLD, whereas 6/12 patients were classiﬁed SD with IU and AASLD
Table 4).
4/26 patients classiﬁed with IU as PR were described as SD with
hoi, 10/14 SD patients measured with Choi were SD according to
U, the other 4 patients were PR with IU. 2/4 PD patients according
o Choi were SD with IU (Table 5).
From 18 SD patients measured according to AASLD only 8/18
ere SD based on Choi, but 10/18 PR with Choi. 6/14 SD patients
ith Choi were described as pD with AASLD (Table 6).
Table 7 illustrates signiﬁcant changes of HU measured with Choind IU and AFP measurements (ng/ml) from baseline to follow-up
nvestigations. Between baseline and follow-up there were no sig-
iﬁcant differences of diameter-measurments according to AASLD.IU (HU) 34.2 ± 12.7 12.4 ± 9.3 <0.005
AFP  (ng/ml) 438 ± 301 134 ± 73 <0.005
4. Discussion
The study examined the possibilities of DECT in the assessment
of therapy response of hepatocellular carcinoma after radioem-
bolization (RE).
In recent years, the importance of tumor perfusion in the assess-
ment of response to therapy has more and more increased. Here,
the changes in CT density values of the tumors as meaningful
parameters were used in addition to size changes [8–15]. With
the present study we  now demonstrate that dual-energy CT can
provide important information about the contrast uptake of hep-
atocellular carcinomas. Others studies showed that volumetric
iodine uptake (VIU) is likely to be an optimized tumor response
biomarker, ﬁrst reﬂecting vital tumor burden in HCC [7]. The
iodine uptake (IU) can also be quantiﬁed and visualized optically
[21,28–31] (Figs. 2–4 ). The decisive advantage of DECT is that a
native examination of the tumors before contrast injection to assess
the iodine uptake is not necessary, because materials as iodine can
be quantiﬁed using information of the different CT-tubes [32].
Our study has shown that the quantiﬁed iodine uptake of
the tumors using DECT as an expression of tumor-perfusion is
a promising parameter. In contrast to the absolute CT density
value changes measured by Choi IU measurements with DECT led
to changes in classiﬁcations of patients in tumor response after
RE. Thus, we  have shown that more patients by IU were classi-
ﬁed as SD versus PD and PR versus SD. We attribute this to the
more detailed consideration of the HU differences between the vir-
tual native and contrast-enhanced series generated by DECT. Thus,
therapy-induced necrosis was  detected more precise with IU than
by absolute density measurements according to Choi.
Account of tumor perfusion can decisive inﬂuence the assess-
ment of treatment response as other studies could prove. For
example, patients can be rated as PR, when a decrease in the sum
of the lesion densities (HU) of ≥15% can be found, regardless of
changes in tumor size [10].
Other studies showed that both VIU (volume iodine uptake) and
Choi can reﬂect the iodinated contrast medium accumulation in
the vital parts of tumor and thus can be used to evaluate the intra-
tumoral blood and vascular changes. However, the mean tumor
density of Choi reﬂects in their opinion not only the accumulation
of iodine, but also the mixed internal materials of tumor, as vital
tumor, necrosis tissue even hemorrhage caused by targeted thera-
pies. Intratumoral hemorrhage could raise the tumor density and
could mislead the evaluation of therapy response [7].
Our study has some limitations. First, only responses of target
lesions were evaluated and the overall response of patients was not
evaluated. Larger patient sampling and overall response of patient
should be done in future studies.
Second, future studies should clarify how the iodine uptake cor-
relates with histopathological changes under therapy. We  have not
made any histological examination.
Additionally, further quantitative studies should correlate IU
with other independent tumor response parameters, such as over-
all survival, to deﬁne iodine-uptake thresholds more appropriate
for the different response categories, and to evaluate the value of IU
as a more independent tumor response parameter for monitoring
of HCC targeted therapy.
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Fig. 2. HCC in segment 6 of the liver. Overlay images generated with DECT before (a.) and after RE (b.).
Fig. 3. HCC in segment 7/8 of the liver. Overlay images generated with DECT before (a.) and after RE (b.).
Fig. 4. HCC in segment 5 and 6 of the liver. Overlay images generated with DECT before (a.; c.) and after RE (b.; d.).
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Conclusion: Iodine uptake (IU) in HCC measured and visualized
ith DECT is a promising imaging method for the assessment of
reatment response after radioembolisations. As IU reﬂects vital
umor burden in HCC, it is likely to be an optimal tumor response
iomarker in HCC.
.1. Clinical relevance
. Using the dual energy CT treatment monitoring can be done
more precisely.
. Contrast enhancement can be quantiﬁed without prior native
images.
. Patients beneﬁt from a more accurate treatment monitoring and
less radiation exposure.
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